Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
Eisai (4523 JT) presented the results of its Clarity AD trials for lecanemab to an Alzheimer’s Disease conference in San Francisco on 29 Nov. Unsurprisingly, since it met its primary and secondary endpoints, the drug would appear to work. The only problem is the issue of “Why doesn’t it work better”? And the answer to that is “Actually, it might, but the trial ended too soon”.
The general evaluation of EISAI (JP), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date April 1, 2022, the closing price was JPY 5,734.0...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
In an enormous announcement, Eisai’s partner Biogen said that long study data delivered on aducanumab – months after the drug had been pulled from trials for inefficaciousness – does seem to work if (1) used early enough, and (2) used a high enough dosage. In this report, Pelham Smithers discusses the potential green field in AD treatment, models the impact on Eisai’s earnings if the drug is FDA approved and puts the valuations into perspective against its peers.
Japan Market Comment by Pelham Smithers, Julie Boote and Joel Scheiman Nikkei ¥21,824.03 (+¥354.83 / +1.65%); Topix ¥1,741.30 (+¥25.82/ +1.51%); ¥/$106.59 Tags: Alps (6770 JP), Eisai (4523 JP), Merck (MRK US), Universal Entertainment (6425 JP), Wynn (WYNN US), Ulvac (6728 JP), Tokyo Seimitsu (7729 JP), Canon (7751 JP), Samco (6387 JP), Spotify (SPOT US), Sony (6758 JP), Warner Music (unlisted), Honda (7267 JP), Toyota 7203 JP), Miraial (4238 JP), Samsung (005930 KS), Shin-Etsu Polymer (797...
Japan Market Comment by Pelham Smithers, Julie Boote, Joel Scheiman and Thao Nguyen Nikkei ¥21,368.67 (+¥115.35 / +0.54%); Topix ¥1,709.95 (+¥5.99/ +0.35%); ¥/$105.96 Tags: Capcom (9697 JP), GMO Payment (3769 JP), SBI Holdings (8473 JP), Digital Garage (4819 JP), Kitanotatsujin (2930 JP), Nissan (7201 JP), Renault (RNO FP), Mitsubishi Motors (7211 JP), Ricoh (7752 JP), Fujifilm (4901 JP), Xerox Corp (XRX US), Fuji Xerox, Eisai (4523 JP), Merck (MRK US), Asahi Kasei (3407 JP), LINE (3938 JP...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.